Clinical meaning of sarcopenia in patients undergoing endoscopic treatment
- Author:
Hiroyuki HISADA
1
;
Yosuke TSUJI
;
Hikaru KURIBARA
;
Ryohei MIYATA
;
Kaori OSHIO
;
Satoru MIZUTANI
;
Hideki NAKAGAWA
;
Rina CHO
;
Nobuyuki SAKUMA
;
Yuko MIURA
;
Hiroya MIZUTANI
;
Daisuke OHKI
;
Seiichi YAKABI
;
Yu TAKAHASHI
;
Yoshiki SAKAGUCHI
;
Naomi KAKUSHIMA
;
Nobutake YAMAMICHI
;
Mitsuhiro FUJISHIRO
Author Information
- Publication Type:Review
- From:Clinical Endoscopy 2024;57(4):446-453
- CountryRepublic of Korea
- Language:EN
- Abstract: With increasing global life expectancy, the significance of geriatric assessment parameters has increased. Sarcopenia is a crucial assessment parameter and is defined as the age-related loss of muscle mass and strength. Sarcopenia is widely acknowledged as a risk factor for postoperative complications in diverse advanced malignancies and has a detrimental effect on the long-term prognosis. While most studies have primarily concentrated on the correlation between sarcopenia and advanced cancer, more recent investigations have focused on the relationship between sarcopenia and early-stage cancer. Endoscopic submucosal dissection (ESD), which is less invasive than surgical intervention, is extensively employed in the management of early-stage cancer, although it is associated with complications such as bleeding and perforation. In recent years, several reports have revealed the adverse consequences of sarcopenia in patients with early-stage cancer undergoing ESD. This literature review briefly summarizes the recent studies on the association between sarcopenia and ESD.
